Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Araris Biotech AG has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, so each matter has its own examination setting.
VISHNYAKOVA, ELENA VLADIMIROVNA is the busiest examiner, with 1 pending matter. Counsel can treat the matters separately while assessing whether their biotechnology subject matter presents issues that call for a coordinated portfolio position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VISHNYAKOVA, ELENA VLADIMIROVNA | 1 | 68.3% | +46.6% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19269487 | ANTIBODY-DRUG CONJUGATES USING TWO DIFFERENT TYPES OF TOPOISOMERASE I INHIBITORS | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| 18639584 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19269487 | ANTIBODY-DRUG CONJUGATES USING TWO DIFFERENT TYPES OF TOPOISOMERASE I INHIBITORS | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103§112DP | Non-Final OA | — | Pending | Jul 15, 2025 |
| 18639584 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | GUSTILO, ESTELLA M | 1646 | §102Other | Non-Final OA | — | Pending | Apr 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAraris Biotech AG has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Elena Vladimirovna Vishnyakova has the most, with 1 of Araris Biotech AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
